Leap Therapeutic SEC Filings

Cypherpunk Technologies Inc. (CYPH) director reported significant indirect share sales by affiliated investment entities. On November 17, 2025, HCV VIII Liquidating Trust sold 261,840 shares of common stock at a weighted average price of $3.14 per share, with individual trades ranging from $2.40 to $3.40, as part of its wind up and liquidation. On the same date, HealthCare Ventures IX, L.P. sold 414,479 shares at a weighted average price of $3.14 per share within the same price range, also tied to its liquidation.

Following these transactions, the reporting person is shown as indirectly beneficially owning 416,616 shares through related entities and 2,136 shares through Nine Capital Partners, plus 20,914 shares held directly. The filing notes that beneficial ownership of the fund and trust shares is disclaimed except for the reporter’s proportionate economic interest.

Cypherpunk Technologies Inc. director and reporting person filed a Form 4 after a significant share sale tied to a liquidating trust. On November 17, 2025, HCV VIII Liquidating Trust sold 261,840 shares of Cypherpunk common stock as part of the wind up and liquidation of that entity. The weighted average sale price was $3.14 per share, with individual trades reportedly occurring between $2.40 and $3.40 per share. Following the transaction, the reporting person shows 0 shares beneficially owned, held indirectly. The reporting person is a beneficiary of the HCV Liquidating Trust and may have been deemed to beneficially own the shares sold, but expressly disclaims beneficial ownership except for any proportionate pecuniary interest.

Cypherpunk Technologies Inc. director and senior officer Douglas E. Onsi filed a Form 4 reporting indirect sales of the company’s common stock on November 17, 2025. A liquidating trust, HCV VIII Liquidating Trust, sold 261,840 shares of common stock at a weighted average price of $3.14 per share, with individual trades ranging from $2.40 to $3.40, as part of its wind up and liquidation. On the same date, HealthCare Ventures IX, L.P. sold 414,479 shares of common stock at a weighted average price of $3.14 per share, also in connection with its wind up and liquidation, with trades in the same $2.40 to $3.40 range.

Following these transactions, Douglas E. Onsi reports 106,146 shares held directly, and indirect beneficial ownership of 416,616 shares and 2,136 shares through affiliated entities. He may be deemed to beneficially own the shares held or sold by these entities but disclaims beneficial ownership except to the extent of his proportionate pecuniary interest.

Cypherpunk Technologies Inc. reported that it has expanded its cryptocurrency treasury by purchasing an additional $18 million of Zcash (ZEC) on November 18, 2025. This new purchase totals 29,869.29 ZEC at an average price of $602.63 per ZEC. The company previously acquired 203,775.27 ZEC for approximately $50 million at an average price of $245.37 per ZEC. After the latest transaction, Cypherpunk now holds 233,644.56 ZEC at an overall average cost of $291.04 per ZEC, representing 1.43% ownership of the Zcash network.

Cypherpunk Technologies Inc. (CYPH)11/11/2025, Director and officer Douglas E. Onsi received 2,087,287 restricted stock units (RSUs) under the company’s 2016 Equity Incentive Plan for $0 consideration.

The RSUs vest as follows: 12/36th on October 8, 2026 and 1/36th on the 8th day of each month thereafter, subject to continued service. Vested RSUs will be settled in common stock at the earliest of: the first payroll period after the end of the reporting person’s employment or service, the first payroll period on or after the 8th day of June following any applicable Vesting Date, or the first payroll period on or after the 8th day of December following any applicable Vesting Date.

Cypherpunk Technologies Inc. (CYPH) reported a director equity grant. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) under the Company’s 2022 Equity Incentive Plan for no consideration, each RSU deliverable into one share of common stock.

The RSUs vested at issuance on the grant date. Settlement into common shares will occur as soon as practicable after the earlier of the fifth business day following the director’s service ending or the first annual meeting of stockholders following the grant date.

Cypherpunk Technologies Inc. (CYPH) reported a director equity grant. A Form 4 discloses an award of 74,700 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan. Each RSU converts into one share of common stock, par value $0.001, and the award was granted for no consideration.

The RSUs vested at issuance on the grant date and will be settled in common stock as soon as practicable after the earlier of (i) the fifth business day following the director’s departure from the Board or (ii) the first annual meeting of stockholders following the grant date. Following the reported transaction, the director holds 74,700 derivative securities on a direct ownership basis.

Cypherpunk Technologies (CYPH)November 11, 2025, the director received 74,700 restricted stock units (RSUs) for no cash consideration under the 2022 Equity Incentive Plan. The RSUs vested at issuance.

Settlement into common stock will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the Board or the first annual stockholder meeting after the grant date.

Cypherpunk Technologies Inc. (CYPH) reported an insider equity grant. A director received 74,700 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan for $0 consideration, with each RSU settling 1-for-1 into common stock.

The RSUs vested at issuance. Settlement will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the board or the first annual meeting of stockholders following the grant date. Following the transaction, the filing lists 74,700 derivative securities held direct.